TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7573259

Group type: EXPERIMENTAL
Intervention: 60 mg of aspirin
Number of subjects: 495

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 495

Group type: EXPERIMENTAL
Intervention: Angiotensin sensitivity test
Number of subjects: 495
Study: 2183591

Group type: EXPERIMENTAL
Intervention: Oral sodium phosphate
Number of subjects: 102

Group type: COMPARATOR
Intervention: Golytely (standard polyethylene glycol-based lavage solution)
Number of subjects: 102
Study: 77993

Group type: EXPERIMENTAL
Intervention: Local zinc sulphate application
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo ointment application
Number of subjects: 10
Study: 30801390

Group type: EXPERIMENTAL
Intervention: EZ-close Port-site Closure System
Number of subjects: 0

Group type: COMPARATOR
Intervention: Carter-Thomason CloseSure System (CT)
Number of subjects: 0
Study: 28953989

Group type: EXPERIMENTAL
Intervention: Collaborative care model (CCM)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 114
Study: 25070538

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 23641793

Group type: EXPERIMENTAL
Intervention: Oral levofloxacin 500 mg 1*1 for 21 days
Number of subjects: 140

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 140
Study: 17218327

Group type: EXPERIMENTAL
Intervention: Manual therapy plus ultrasound (US)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Manual therapy plus placebo ultrasound (placebo US)
Number of subjects: 221
Study: 15234509

Group type: EXPERIMENTAL
Intervention: Lidocaine 1% with adrenaline (1:200,000)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Lidocaine buffered with 8.4% NaHCO3 at a 5:1 ratio
Number of subjects: 21
Study: 11145762

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (biventricular pacing)
Number of subjects: 500
Study: 9178343

Group type: EXPERIMENTAL
Intervention: Subjects described as likely to respond to suggestion
Number of subjects: 30

Group type: COMPARATOR
Intervention: Subjects described as unlikely to respond to suggestion
Number of subjects: 30
Study: 8240146

Group type: EXPERIMENTAL
Intervention: Intravenous aminophylline infusion adjusted to maintain therapeutic levels.
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo (control group).
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Both groups received nebulised salbutamol and ipratropium bromide, intravenous hydrocortisone, and oxygen.
Number of subjects: 59
Study: 3927692

Group type: EXPERIMENTAL
Intervention: CoQ10 (150 mg/day in 3 daily doses) for 4 weeks
Number of subjects: 12
Study: 30880943

Group type: EXPERIMENTAL
Intervention: Extrafine BDP/FF/G
Number of subjects: 0
Study: 27913870

Group type: EXPERIMENTAL
Intervention: Hatha yoga (HY)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Aerobic/strengthening exercises (ASE)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Education control
Number of subjects: 83
Study: 26681678

Group type: EXPERIMENTAL
Intervention: trabectedin 1.3 mg/mq i.v. q 3 weeks
Number of subjects: 100
Study: 24438360

Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Trisodium citrate
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: No anticoagulation
Number of subjects: 38
Study: 22099522

Group type: EXPERIMENTAL
Intervention: Early neurodevelopmental intervention
Number of subjects: 201

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 201
Study: 19204201

Group type: EXPERIMENTAL
Intervention: Docetaxel/Cyclophosphamide (TC)
Number of subjects: 1016

Group type: COMPARATOR
Intervention: Doxorubicin/Cyclophosphamide (AC)
Number of subjects: 1016
Study: 17549328

Group type: EXPERIMENTAL
Intervention: Intramuscular stimulation
Number of subjects: 43

Group type: COMPARATOR
Intervention: 0.5% lidocaine injection
Number of subjects: 43
Study: 15308432

Group type: EXPERIMENTAL
Intervention: Antianginal medications (beta-blockers, calcium antagonists, long-acting nitrates)
Number of subjects: 7038

Group type: EXPERIMENTAL
Intervention: Antianginal medications prescribed
Number of subjects: 7038
Study: 11551104

Group type: COMPARATOR
Intervention: 35delG mutation screening in GJB2 gene
Number of subjects: 4123
Study: 9842806

Group type: EXPERIMENTAL
Intervention: Desflurane 4% (n = 31)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Propofol infusion 100 microg kg(‐1) min(‐1) (n = 29)
Number of subjects: 60
Study: 8131635

Group type: EXPERIMENTAL
Intervention: Fluconazole (400 mg/day)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 10303909

Group type: EXPERIMENTAL
Intervention: Second-look laparotomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 162672

Group type: EXPERIMENTAL
Intervention: ibuprofen (900‐1800 mg/day)
Number of subjects: 218

Group type: COMPARATOR
Intervention: indomethacin (75‐150 mg/day)
Number of subjects: 218

Group type: COMPARATOR
Intervention: indomethacin
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: ibuprofen
Number of subjects: 218
Study: 31233885

Group type: EXPERIMENTAL
Intervention: ALA-PDT combined with limited excision
Number of subjects: 8
Study: 28151896

Group type: EXPERIMENTAL
Intervention: Distal Gastrectomy (DG)
Number of subjects: 1262

Group type: COMPARATOR
Intervention: Total Gastrectomy (TG)
Number of subjects: 1262
Study: 26036903

Group type: EXPERIMENTAL
Intervention: Primary outcome paper
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ancillary publications utilizing specimens from the repository
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline paper and secondary hypotheses papers
Number of subjects: 0
Study: 23771607

Group type: EXPERIMENTAL
Intervention: ISO-coupled movements
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ANTI-coupled movements
Number of subjects: 0
Study: 21372745

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Wait-list control (WLC)
Number of subjects: 110
Study: 19013758

Group type: EXPERIMENTAL
Intervention: Daily 16-week home-based hand exercise
Number of subjects: 46

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 46
Study: 16625231

Group type: EXPERIMENTAL
Intervention: Cabergoline (0.5‐1 mg weekly for 6 months)
Number of subjects: 402

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Cabergoline
Number of subjects: 402
Study: 15043534

Group type: COMPARATOR
Intervention: Brimonidine 0.2%
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Unoprostone 0.15%
Number of subjects: 33
Study: 11769817

Group type: EXPERIMENTAL
Intervention: Clozapine 6 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Clozapine 3 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Clozapine 3 mg and 6 mg
Number of subjects: 15
Study: 9231677

Group type: COMPARATOR
Intervention: External irradiation alone (planned dose 60 Gy)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: External irradiation plus additional HDR brachytherapy (4.8 Gy each)
Number of subjects: 98
Study: 8220800

Group type: EXPERIMENTAL
Intervention: Open challenge with a mixture of food preservatives, colourings and flavours (fizzy lemonade)
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Double-blind placebo-controlled challenge with gelatine capsules
Number of subjects: 271
Study: 3690941

Group type: EXPERIMENTAL
Intervention: 1000 mg acetaminophen
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 60 mg codeine
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 1000 mg acetaminophen plus 60 mg codeine
Number of subjects: 120

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 120
Study: 30355362

Group type: EXPERIMENTAL
Intervention: BIOF2
Number of subjects: 24

Group type: COMPARATOR
Intervention: NSAIDs
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Arthroplasty
Number of subjects: 24
Study: 26996315

Group type: EXPERIMENTAL
Intervention: iTBS (intermittent Theta Burst Stimulation) over the left PFC (F3)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Sham-controlled activating protocol
Number of subjects: 41
Study: 24342152

Group type: EXPERIMENTAL
Intervention: HMS (hemostasis management system) measurements
Number of subjects: 38

Group type: COMPARATOR
Intervention: ACT (activated coagulation time) based management
Number of subjects: 38
Study: 22898215

Group type: EXPERIMENTAL
Intervention: Adalimumab (40 mg every other week for 12 weeks)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 21116022

Group type: EXPERIMENTAL
Intervention: n-3 long-chain polyunsaturated fatty acids (LCPUFA) supplementation (600 mg EPA and 400 mg DHA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: n-3 long-chain polyunsaturated fatty acids (LCPUFA) supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18175744

Group type: EXPERIMENTAL
Intervention: High-glycemic-index diet
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Low-glycemic-index diet
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate, high-monounsaturated-fat diet
Number of subjects: 162
Study: 15674155

Group type: EXPERIMENTAL
Intervention: Standard parenteral antibiotics for 2 weeks followed by oral antibiotics for 4 weeks (Group I)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Local gentamicin‐polymethylmethacrylate bead implantation (Group II)
Number of subjects: 23
Study: 12646232

Group type: EXPERIMENTAL
Intervention: sn-1,3-diacylglycerol (DAG)
Number of subjects: 49

Group type: COMPARATOR
Intervention: triacylglycerol (TAG)
Number of subjects: 49
Study: 10765510

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 gel in the morning
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 gel in the evening
Number of subjects: 126
Study: 8774203

Group type: EXPERIMENTAL
Intervention: Ardeparin (low-molecular-weight heparin), 0.005 mL/kg (50 anti-Xa U/Kg), administered subcutaneously twice daily for 14 days or until discharge.
Number of subjects: 246

Group type: COMPARATOR
Intervention: Placebo (graduated compression stockings alone), administered subcutaneously twice daily for 14 days or until discharge.
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Ardeparin (low-molecular-weight heparin)
Number of subjects: 246

Group type: COMPARATOR
Intervention: Placebo (graduated compression stockings alone)
Number of subjects: 246
Study: 1354372

Group type: EXPERIMENTAL
Intervention: Suprathreshold masking release for gap detection in conditions resulting in CMR
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Suprathreshold masking release for gap detection in conditions not resulting in CMR
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low levels of stimulation
Number of subjects: 0
Study: 6338868

Group type: EXPERIMENTAL
Intervention: 4',6-Dichloroflavan (1 mg/kg, 3 times per day for 3 doses before and 13 doses after challenge)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 63
Study: 31803478

Group type: EXPERIMENTAL
Intervention: Reduced HUNT model
Number of subjects: 4051

Group type: COMPARATOR
Intervention: NLST criteria
Number of subjects: 4051

Group type: COMPARATOR
Intervention: NELSON criteria
Number of subjects: 4051
Study: 29036621

Group type: EXPERIMENTAL
Intervention: Whole-neck postoperative radiotherapy
Number of subjects: 275

Group type: COMPARATOR
Intervention: Limited field postoperative radiotherapy
Number of subjects: 275
Study: 25549767

Group type: EXPERIMENTAL
Intervention: Planning-focused cognitive behavioral therapy (CBT)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Solution-focused treatment (SFT)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Planning-focused CBT
Number of subjects: 159
Study: 23307206

Group type: EXPERIMENTAL
Intervention: InflammaDry
Number of subjects: 206

Group type: COMPARATOR
Intervention: Clinical assessment
Number of subjects: 206
Study: 21816474

Group type: EXPERIMENTAL
Intervention: Child-parent psychotherapy (CPP)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Comparison group (monthly case management plus referrals to community services)
Number of subjects: 75
Study: 18070948

Group type: EXPERIMENTAL
Intervention: Cooled ablation (open irrigation at 15 ml/min, 45 degrees C, 35 (5) W)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Standard temperature-controlled 4 mm tip catheter ablation (55 degrees C, 35 (5) W)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Cooled ablation
Number of subjects: 36

Group type: COMPARATOR
Intervention: Standard temperature-controlled 4 mm tip catheter ablation
Number of subjects: 36
Study: 16773453

Group type: EXPERIMENTAL
Intervention: Tacrolimus ointment
Number of subjects: 9

Group type: COMPARATOR
Intervention: Hydrocortisone butyrate ointment
Number of subjects: 9
Study: 12373659

Group type: EXPERIMENTAL
Intervention: Gabapentin (up to 1,800 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 0
Study: 10228111

Group type: EXPERIMENTAL
Intervention: Budesonide (400 microgram/d for 8 days)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Allergen inhalation
Number of subjects: 9
Study: 7671879

Group type: EXPERIMENTAL
Intervention: Prior exercise with 2510-kJ meal
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Prior exercise with 5020-kJ meal
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control with 2510-kJ meal
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control with 5020-kJ meal
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: 5020-kJ meal in two portions after exercise
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: 5020-kJ meal in one portion after exercise
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: First portion of 2510-kJ meal
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Second portion of 2510-kJ meal
Number of subjects: 2
Study: 2402214

Group type: EXPERIMENTAL
Intervention: Inosine supplementation (6,000 mg.d‐1 for 2 d)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 9
Study: 7446607

Group type: EXPERIMENTAL
Intervention: Intrauterine irrigation with cefamandole nafate solution
Number of subjects: 90

Group type: COMPARATOR
Intervention: Irrigation with normal saline solution
Number of subjects: 90

Group type: COMPARATOR
Intervention: No irrigation
Number of subjects: 90
Study: 6342564

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 31017869

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) score
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Maximal aerobic capacity (VO2max)
Number of subjects: 294

Group type: COMPARATOR
Intervention: BMI and age correlation
Number of subjects: 294

Group type: COMPARATOR
Intervention: BMI and VO2max correlation
Number of subjects: 294

Group type: COMPARATOR
Intervention: BMI and total PA score correlation
Number of subjects: 294
Study: 30540834

Group type: EXPERIMENTAL
Intervention: Personal experience
Number of subjects: 1030

Group type: EXPERIMENTAL
Intervention: Reading online content
Number of subjects: 1030

Group type: EXPERIMENTAL
Intervention: Watching visual media online
Number of subjects: 1030

Group type: EXPERIMENTAL
Intervention: Science organizations
Number of subjects: 1030

Group type: EXPERIMENTAL
Intervention: Universities
Number of subjects: 1030

Group type: EXPERIMENTAL
Intervention: Friends/family
Number of subjects: 1030

Group type: EXPERIMENTAL
Intervention: Demographics (education level, age)
Number of subjects: 1030

Group type: EXPERIMENTAL
Intervention: Demographics (education, race, age, size of residence)
Number of subjects: 1030
Study: 26860124

Group type: EXPERIMENTAL
Intervention: Vorapaxar monotherapy
Number of subjects: 0
Study: 24638865

Group type: EXPERIMENTAL
Intervention: Group A (abnormal clinical presentation)
Number of subjects: 236

Group type: COMPARATOR
Intervention: Group B (clinically typical nevi)
Number of subjects: 236
Study: 22813609

Group type: EXPERIMENTAL
Intervention: Midodrine hydrochloride
Number of subjects: 57
Study: 20412603

Group type: EXPERIMENTAL
Intervention: Biscuits fortified with vitamin A at 30% of the RDA once a day for 9 months
Number of subjects: 580

Group type: EXPERIMENTAL
Intervention: Biscuits fortified with vitamin A at 100% of the RDA once a day for 3 months
Number of subjects: 580

Group type: EXPERIMENTAL
Intervention: Biscuits containing 20,000 IU of vitamin A once a week for 3 months
Number of subjects: 580

Group type: EXPERIMENTAL
Intervention: Single 200,000 IU vitamin A capsule administration
Number of subjects: 580
Study: 19227864

Group type: EXPERIMENTAL
Intervention: Diet therapy containing a specialized product enriched with vitamins and minerals (50% calcium, 20% protein, 17-60% of 11 minerals, and 11 vitamins)
Number of subjects: 0
Study: 15704058

Group type: EXPERIMENTAL
Intervention: Bosentan (500 mg twice daily, titrated slowly or rapidly)
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Bosentan
Number of subjects: 370

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 370
Study: 15846939

Group type: EXPERIMENTAL
Intervention: Cuban trivalent inactivated vaccine against human leptospirosis (vax‐SPIRAL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Russian-made vaccine
Number of subjects: 0
Study: 10350029

Group type: EXPERIMENTAL
Intervention: Alprazolam 2 mg during the midluteal phase of the menstrual cycle
Number of subjects: 12

Group type: COMPARATOR
Intervention: Alprazolam 2 mg during the midfollicular phase of the menstrual cycle
Number of subjects: 12
Study: 8622050

Group type: EXPERIMENTAL
Intervention: Standard informed consent procedures plus a supplementary, telephone‐based contact with an oncology nurse
Number of subjects: 180

Group type: COMPARATOR
Intervention: Standard informed consent procedures based on verbal explanations from the treating physician plus written information
Number of subjects: 180
Study: 1760833

Group type: EXPERIMENTAL
Intervention: Intravenous isosorbide dinitrate (ISDN) at a dose of 10 mg/h over the first 3 days of infarction
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Number of subjects: 115

Group type: COMPARATOR
Intervention: Anticoagulants only
Number of subjects: 115
Study: 7333402

Group type: EXPERIMENTAL
Intervention: 8-methoxypsoralen solution
Number of subjects: 8

Group type: COMPARATOR
Intervention: Commercial solid formulations of 8-methoxypsoralen
Number of subjects: 8
Study: 31359271

Group type: EXPERIMENTAL
Intervention: 1 mg of oral risperidone
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Dose adjustment of risperidone by -25% for poor metabolizers and by -10% for intermediate metabolizers
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Risperidone/9-OH-RIS ratio
Number of subjects: 71
Study: 31524664

Group type: EXPERIMENTAL
Intervention: Combined arm cycling and task-oriented exercises
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 20
Study: 29630457

Group type: EXPERIMENTAL
Intervention: Clinicians rating the acceptability of withholding surgery when prognosis is certain to be poor.
Number of subjects: 818

Group type: EXPERIMENTAL
Intervention: Nonclinicians rating the acceptability of withholding surgery.
Number of subjects: 818

Group type: EXPERIMENTAL
Intervention: Clinicians rating the acceptability of withholding surgery based on prognosis certainty.
Number of subjects: 818

Group type: COMPARATOR
Intervention: Effect of surrogate distress on clinician ratings.
Number of subjects: 818
Study: 26177825

Group type: EXPERIMENTAL
Intervention: Psychosocial intervention including education, counseling, and social support (16 days over the first 2 years)
Number of subjects: 236

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Psychosocial intervention
Number of subjects: 236
Study: 24984211

Group type: EXPERIMENTAL
Intervention: Self-referral
Number of subjects: 12000

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 12000
Study: 22340088

Group type: EXPERIMENTAL
Intervention: Four-component environmental intervention at the worksite level over a two-year period.
Number of subjects: 6

Group type: COMPARATOR
Intervention: No-contact control group.
Number of subjects: 6
Study: 20576364

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17416764

Group type: EXPERIMENTAL
Intervention: 12-week aerobic exercise training
Number of subjects: 32

Group type: COMPARATOR
Intervention: Usual lifestyle (control)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Change in lean body mass over the intervention
Number of subjects: 32
Study: 16360084

Group type: EXPERIMENTAL
Intervention: Early protocol (shock delivered mean 6.8 hours after AF onset)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Delayed protocol (shock delivered mean 34.7 hours after AF onset)
Number of subjects: 44
Study: 12441805

Group type: EXPERIMENTAL
Intervention: Zidovudine (short course)
Number of subjects: 185
Study: 10732590

Group type: EXPERIMENTAL
Intervention: Haid holder
Number of subjects: 68

Group type: COMPARATOR
Intervention: Other tube holders
Number of subjects: 68
Study: 7773832

Group type: EXPERIMENTAL
Intervention: CGA with in‐hospital and post discharge management by a home intervention team (HIT)
Number of subjects: 540

Group type: COMPARATOR
Intervention: CGA with recommendations and usual care at home
Number of subjects: 540

Group type: COMPARATOR
Intervention: Usual hospital and home care
Number of subjects: 540
Study: 2338688

Group type: EXPERIMENTAL
Intervention: Combinations of nitrendipine, atenolol, and hydrochlorothiazide
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Combinations containing hydrochlorothiazide
Number of subjects: 24
Study: 117482

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Amoxapine
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control (Healthy Volunteers)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Patients
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Imipramine vs Amoxapine
Number of subjects: 13
Study: 31057081

Group type: EXPERIMENTAL
Intervention: Mobile Health (mHealth) intervention
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard follow-up group
Number of subjects: 30